You are here: Industry Insights > AML

News List

Helsinn Grants Exclusive Licensing Rights to Menarini for Pracinostat americanpharmaceuticalreview
December 28, 2018
Helsinn and Menarini announced that Berlin Chemie AG, the German company of the Menarini Group, has been granted exclusive licensing rights to....
Daiichi Sankyo Initiates Study of Two Investigational Agents for Patients with AML americanpharmaceuticalreview
December 24, 2018
Daiichi Sankyo announced that the first patient has been dosed in the first novel-novel combination study evaluating two investigational agents within its AML Franchise......
Daiichi Sankyo claims speedy review for AML drug in Europe pharmaphorum
December 13, 2018
Japan’s Daiichi Sankyo is looking at a reduced review time for its acute myeloid leukaemia (AML) drug quizartinib in Europe, the top prospect in its new oncology pipeline.....
Tailored treatment for acute myeloid leukaemia europeanpharmaceuticalreview
December 12, 2018
The screening of leukaemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for AML…
Astellas Launches XOSPATA for Relapsed/Refractory AML with a FLT3 Mutation americanpharmaceuticalreview
December 12, 2018
Astellas Pharma announced that XOSPATA (gilteritinib) is now available for prescription in the United States for the treatment of adult patients who have relapsed .....
Amgen unveils double whammy of data for its investigational cancer immunotherapies at ASH 2018 pharmafile
December 07, 2018
Amgen has presented the first clinical data at the American Society of Hematology (ASH) Annual Meeting 2018 for two investigational novel bispecific T cell engager (BiTE) immunotherapies...
Johnson & Johnson pays $300m to develop cusatuzumab pharmatimes
December 06, 2018
Johnson & Johnson's Janssen has entered into an agreement potentially worth up to $1.6 billion to develop and market Argenx' cusatuzumab for a number of cancers, including haematological malignancies.
Astellas’ Xospata wins AML approval, with Daiichi close behind fiercepharma
December 05, 2018
On an acute myeloid leukemia (AML) roll, the FDA has green-lighted Astellas’ Xospata, also known as gilteritinib. For Astellas, it marks the first step toward challenging Novartis’ Rydapt and likely just a slim head start against Daiichi Sankyo.
91 percent response rate for venetoclax against newly diagnosed AML in older adults worldpharmanews
November 30, 2018
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML).
FDA Approves Gilteritinib americanpharmaceuticalreview
November 30, 2018
On November 28, 2018, the Food and Drug Administration (FDA) approved gilteritinib (XOSPATA, Astellas Pharma) for treatment of adult patients who have relapsed or refractory.......

Previous page 1 2 3 4 5 6 7 8 9 10 Next page